MOBILE VIEW  | 

VENEZUELAN EQUINE ENCEPHALITIS

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Venezuelan equine encephalitis (VEE) is an arthropod-borne alphavirus, and a member of the Togaviridae family. VEE is characterized by sudden onset of a flu-like illness with malaise, high fevers, chills, severe headache, photophobia and myalgias, which may be followed by nausea, vomiting, cough, sore throat, and diarrhea. During the flu-like illness stage, some patients may exhibit evidence of CNS involvement, which may progress to severe encephalitis.

Specific Substances

    1) VEE
    2) Venezuelan equine encephalitis

Available Forms Sources

    A) FORMS
    1) The causative agent of Venezuelan equine encephalitis is an alphavirus in the Togaviridae family (Douglas, 1996). This virus is a 40- to 45-nm, single-stranded RNA virus (Sanford, 1994).
    B) SOURCES
    1) Vectors for transmission of the virus include a large variety of mosquito vectors, including species of the general Aedes, Psorophora, and Mansonia, which transmit subtypes IAB and IC during epizootic epidemics (Douglas, 1996).
    2) Enzootic transmission cycles involving Culex (Melanoconion) species mosquitoes, small forest rodents and marsupials have caused subtype II viral infections in Florida (Douglas, 1996).
    C) USES
    1) Biological warfare - In the United States, Venezuelan equine encephalitis (VEE) was weaponized in the 1950's and 1960's prior to termination of the offensive biological warfare program. Other countries have been, or may be suspected to have weaponized this agent. VEE could be produced in either a wet or dried form and stabilized for use as a biological weapon (USAMRIID, 1999; ((Anon, 1999)).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) BACKGROUND: Venezuelan equine encephalitis (VEE) is caused by an RNA arbovirus (name from "arthropod borne viruses") of the alphavirus genus which is a member of the Togaviridae family. The causative agent of VEE is a 40- to 45-nm, single-stranded RNA virus.
    B) TRANSMISSION: Alphaviruses are transmitted by the bite of a mosquito. Equidae or other mammals serve as amplifying hosts and source of mosquito infection. During epizootic epidemics, a large variety of mosquito vectors transmit subtypes IAB and IC of the VEE.
    C) VECTOR: Vectors for transmission of the virus include a large variety of mosquito vectors, including species of the general Aedes, Psorophora, and Mansonia, which transmit subtypes IAB and IC during epizootic epidemics.
    D) EPIDEMIOLOGY: Historically, large equine epizootics have occurred at 5 to 10 year intervals in Venezuela, Columbia, Ecuador, and Peru prior to 1973, with mortality rates as high as 40%.
    1) DISTRIBUTION: Major epidemics can occur periodically and somewhat sporadically when various strains can occur in equids. In tropical areas, VEE cases can often overlap with dengue fever and malaria because the signs and symptoms of acute febrile illness are similar; therefore, cases may be underreported in some areas where clinical awareness and laboratory studies are lacking.
    2) CASE FATALITY RATE: Overall case fatality rate is less than 1%, with most of the fatalities reported in children. Cases presenting with encephalitis may have a mortality rate approaching 20%.
    E) WITH POISONING/EXPOSURE
    1) INCUBATION PERIOD: 2 to 5 days.
    2) ADVERSE EFFECTS: FLU-LIKE ILLNESS: Following the incubation period, a sudden onset of a flu-like illness occurs, with chills and spiking fever, malaise, photophobia and severe headache. This is followed by myalgias, sore throat, coughing, nausea, vomiting, and sometimes diarrhea. Tachycardia, conjunctival infection, and sometimes nonexudative pharyngitis may be seen on physical examination. During the flu-like illness stage, some patients may exhibit evidence of CNS involvement, which may progress to severe encephalitis. In severe cases, residual neurologic damage may also occur. Children are more likely to develop VEE-associated encephalitis. CNS effects including disorientation, ataxia, mental depression, and seizures can be develop in up to 14% of infected individuals, especially in children. COMMON: Lymphadenopathy. INFREQUENT: Less common effects include photophobia, seizures, confusion, coma, tremors, and diplopia. DURATION: The acute phase lasts up to 4 to 6 days.
    3) CONVALESCENT PERIOD: After 4 to 6 days the acute illness subsides, and convalescent signs/symptoms, including asthenia and lethargy, may continue for up to 3 weeks. In more severe cases, symptoms may last up to 8 days. Full recovery usually takes 1 to 2 weeks. Excellent short-term and long-term immunity results on recovery from infection.
    4) BIPHASIC PERIOD: Occasionally a biphasic course is noted, with acute symptoms reappearing following a brief remission, within a week after initial onset.
    5) BIOLOGIC TERRORISM: A biological terrorist attack with aerosolized virus may cause infections of the olfactory nerve and spread directly to the CNS, resulting in an associated high morbidity and mortality.
    6) PREGNANCY: Severe congenital neuroanatomical anomalies or fetal demise may occur if VEE infection occurs during pregnancy.
    0.2.3) VITAL SIGNS
    A) Chills and fever and increased pulse are common.
    0.2.13) HEMATOLOGIC
    A) Low peripheral leukocyte count has been reported in severe cases.
    0.2.20) REPRODUCTIVE
    A) Fetal encephalitis and hydranencephaly has been reported. VEE virus may be embryotoxic, fetotoxic, and teratogenic to humans.

Laboratory Monitoring

    A) Monitor vital signs, including temperature and pulse.
    B) No specific studies are needed in most patients that develop mild flu-like illness. Monitor fluid status and electrolytes in patients that develop significant vomiting and/or diarrhea.
    C) Monitor liver function tests and complete blood count as indicated.
    D) Monitor for respiratory depression and hypoxia (pulse oximetry or arterial blood gases) in any patient with encephalitis.
    E) Obtain cranial CT and lumbar puncture in patients with altered mental status.
    F) Diagnosis may be established by electron microscopic identification of virus particles isolated from blood or throat swabs obtained in the acute phase of illness. Serological antibody tests confirm the diagnosis and may be more practical. Detection of virus-specific IgM antibody in cerebrospinal fluid is diagnostic.

Treatment Overview

    0.4.3) INHALATION EXPOSURE
    A) SUMMARY
    1) Although the primary mechanism of infection is via bites from a carrier mosquito, a secondary, although rare, mechanism of infection may be through respiratory droplets.
    2) Treatment should include recommendations listed in the BITES/STINGS EXPOSURE section when appropriate.
    0.4.4) EYE EXPOSURE
    A) Exposures of the conjunctiva to the virus causing VEE should be immediately irrigated with normal saline or water.
    B) Treatment should include recommendations listed in the BITES/STINGS EXPOSURE section when appropriate.
    0.4.5) DERMAL EXPOSURE
    A) OVERVIEW
    1) Dermal sites, particularly where breaks in skin integrity occur, exposed to blood, body fluids, secretions, or excretions from patients with suspected VEE should be immediately washed with soap and water.
    2) Treatment should include recommendations listed in the BITES/STINGS EXPOSURE section when appropriate.
    0.4.7) BITES/STINGS
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) Treatment is symptomatic and supportive. Monitor vital signs and mental status. Treat fever and pain with analgesics (ie, acetaminophen, NSAIDs). Monitor fluid status and electrolytes if the patient develops significant vomiting and/or diarrhea. Replace volume loss with oral or IV fluids as needed. Acute flu-like symptoms usually resolve in 4 to 6 days. During this phase, some patients may exhibit evidence of CNS involvement, which may progress to severe encephalitis.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) Monitor vital signs and neurologic function. In severe cases, children are more likely to develop VEE-associated encephalitis. CNS symptoms can include disorientation, ataxia, mental depression and seizures. SEIZURES: Treat seizures with IV benzodiazepines. Barbiturates or propofol may be needed if seizures persist or recur.
    C) DECONTAMINATION
    1) PREHOSPITAL: Prehospital GI decontamination including activated charcoal is not indicated. The focus of prehospital care should include supportive care. FIRST RESPONDERS: Any healthcare personnel should follow isolation precautions (ie, includes gloves, gown, mask) and avoid direct contact with blood or bodily fluids of a patient with a suspected VEE infection.
    2) HOSPITAL: GI decontamination is not indicated. HEALTH CARE WORKERS: Barrier techniques and infection control (avoid direct contact with blood or body fluids) are recommended while treating any patient with confirmed or suspected VEE infection. Droplet precautions are indicated in all patients.
    D) AIRWAY MANAGEMENT
    1) VEE infection typically result in cases of mild, self-limiting flu-like illness; airway support is unlikely to be necessary. In cases of airway compromise, supportive measures including endotracheal intubation and mechanical ventilation may be necessary in patients that develop neurologic complications (ie, seizures, encephalitis, coma) that may occur with encephalitic illness. .
    E) ANTIDOTE
    1) There is no specific antidote for VEE. VACCINE: A live, attenuated cell-culture-propagated vaccine, designated TC-83, from subtype IAB, is available to protect at risk laboratory personnel working with the virus in the US.
    F) ENHANCED ELIMINATION
    1) Enhanced elimination is not anticipated to be necessary in most patients that develop a VEE infection.
    G) PATIENT DISPOSITION
    1) HOME CRITERIA: Asymptomatic patients or patients with minimal symptoms may remain at home.
    2) OBSERVATION CRITERIA: Patients with worsening symptoms that do not improve with over-the-counter medications (eg, analgesics, antipyretics) and basic home treatments should go to a healthcare facility for evaluation and treatment. Patients who are stable with improving symptoms may be sent home.
    3) ADMISSION CRITERIA: Unstable patients or those with worsening symptoms should be admitted to the hospital. Those with severe symptoms (eg, seizures, encephalitis, coma) may require an ICU admission. Criteria for discharge include patients that are clinically improving and stable. INHALATION: All patients with suspected inhalational VEE infection should be admitted to an isolated intensive care unit for monitoring.
    4) CONSULT CRITERIA: Infectious disease physicians and/or intensivists may be consulted for advice on treating patients. All suspected cases should be reported to the State health department, which in turn notifies the CDC. Persons with conjunctiva exposure to blood, body fluids, secretions, or excretions from a patient with suspected VEE should receive medical evaluation and follow-up management. Health department personnel will work with the CDC and the attending physician(s) in the treatment of VEE. Poison centers can aid treatment by serving as a public health resource by providing advice to the general public, and working with local and regional health departments.
    5) PATIENT-TRANSFER CRITERIA: If a patient must be transferred, strict isolation procedures should be observed by all personnel involved in the transfer.

Range Of Toxicity

    A) TOXICITY: The number of aerosolized viruses needed to cause viremia in humans is 10 to 100 organisms. Infections chiefly present with chills and fever, malaise, headache, and myalgia, usually self-limited, and resolve over one week. More severe cases progress to encephalitis with severe neurologic abnormalities, including seizures, nystagmus, somnolence, delirium, or meningitis.

Summary Of Exposure

    A) BACKGROUND: Venezuelan equine encephalitis (VEE) is caused by an RNA arbovirus (name from "arthropod borne viruses") of the alphavirus genus which is a member of the Togaviridae family. The causative agent of VEE is a 40- to 45-nm, single-stranded RNA virus.
    B) TRANSMISSION: Alphaviruses are transmitted by the bite of a mosquito. Equidae or other mammals serve as amplifying hosts and source of mosquito infection. During epizootic epidemics, a large variety of mosquito vectors transmit subtypes IAB and IC of the VEE.
    C) VECTOR: Vectors for transmission of the virus include a large variety of mosquito vectors, including species of the general Aedes, Psorophora, and Mansonia, which transmit subtypes IAB and IC during epizootic epidemics.
    D) EPIDEMIOLOGY: Historically, large equine epizootics have occurred at 5 to 10 year intervals in Venezuela, Columbia, Ecuador, and Peru prior to 1973, with mortality rates as high as 40%.
    1) DISTRIBUTION: Major epidemics can occur periodically and somewhat sporadically when various strains can occur in equids. In tropical areas, VEE cases can often overlap with dengue fever and malaria because the signs and symptoms of acute febrile illness are similar; therefore, cases may be underreported in some areas where clinical awareness and laboratory studies are lacking.
    2) CASE FATALITY RATE: Overall case fatality rate is less than 1%, with most of the fatalities reported in children. Cases presenting with encephalitis may have a mortality rate approaching 20%.
    E) WITH POISONING/EXPOSURE
    1) INCUBATION PERIOD: 2 to 5 days.
    2) ADVERSE EFFECTS: FLU-LIKE ILLNESS: Following the incubation period, a sudden onset of a flu-like illness occurs, with chills and spiking fever, malaise, photophobia and severe headache. This is followed by myalgias, sore throat, coughing, nausea, vomiting, and sometimes diarrhea. Tachycardia, conjunctival infection, and sometimes nonexudative pharyngitis may be seen on physical examination. During the flu-like illness stage, some patients may exhibit evidence of CNS involvement, which may progress to severe encephalitis. In severe cases, residual neurologic damage may also occur. Children are more likely to develop VEE-associated encephalitis. CNS effects including disorientation, ataxia, mental depression, and seizures can be develop in up to 14% of infected individuals, especially in children. COMMON: Lymphadenopathy. INFREQUENT: Less common effects include photophobia, seizures, confusion, coma, tremors, and diplopia. DURATION: The acute phase lasts up to 4 to 6 days.
    3) CONVALESCENT PERIOD: After 4 to 6 days the acute illness subsides, and convalescent signs/symptoms, including asthenia and lethargy, may continue for up to 3 weeks. In more severe cases, symptoms may last up to 8 days. Full recovery usually takes 1 to 2 weeks. Excellent short-term and long-term immunity results on recovery from infection.
    4) BIPHASIC PERIOD: Occasionally a biphasic course is noted, with acute symptoms reappearing following a brief remission, within a week after initial onset.
    5) BIOLOGIC TERRORISM: A biological terrorist attack with aerosolized virus may cause infections of the olfactory nerve and spread directly to the CNS, resulting in an associated high morbidity and mortality.
    6) PREGNANCY: Severe congenital neuroanatomical anomalies or fetal demise may occur if VEE infection occurs during pregnancy.

Vital Signs

    3.3.1) SUMMARY
    A) Chills and fever and increased pulse are common.
    3.3.3) TEMPERATURE
    A) Sudden onset of chills and fever occurs following a 2 to 5 day incubation period after exposure (Mangiafico et al, 2002; Douglas, 1996).
    B) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, fever (94%) was the most common event reported (Quiroz et al, 2009).
    3.3.5) PULSE
    A) Pulse rate may be elevated during acute illness (Douglas, 1996).

Heent

    3.4.3) EYES
    A) Conjunctival injection is commonly seen on physical examination during the initial phase of illness (Douglas, 1996). Photophobia and diplopia may occur during the initial onset of illness.
    B) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, retroorbital pain (27%) occurred frequently (Quiroz et al, 2009).
    3.4.6) THROAT
    A) Nonexudative pharyngitis and cough may occur during the acute phase of illness (Douglas, 1996; Sanford, 1994).

Cardiovascular

    3.5.2) CLINICAL EFFECTS
    A) TACHYARRHYTHMIA
    1) WITH POISONING/EXPOSURE
    a) Physical examination during the initial phase of illness commonly reveals tachycardia (Douglas, 1996).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) ACUTE RESPIRATORY INSUFFICIENCY
    1) WITH POISONING/EXPOSURE
    a) Patients who progress to CNS involvement with encephalitis may experience a central respiratory failure (Douglas, 1996).
    B) COUGH
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, cough (3%) occurred rarely (Quiroz et al, 2009).

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) CENTRAL NERVOUS SYSTEM FINDING
    1) WITH POISONING/EXPOSURE
    a) Clinical signs of mild CNS involvement may occur during the early flu-like illness phase and may include headache, somnolence, photophobia, diplopia, and confusion (Mangiafico et al, 2002; Douglas, 1996; Sanford, 1994; Casamassima et al, 1987).
    B) HEADACHE
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by fever, headache, nausea, vomiting, diarrhea, and tremors. Of the 33 cases that exhibited clinical adverse events, headache (55%) was frequently reported (Quiroz et al, 2009).
    C) TREMOR
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, tremors (27%) occurred frequently (Quiroz et al, 2009).
    D) SEIZURE
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, seizures (3%) occurred rarely (Quiroz et al, 2009).
    E) ENCEPHALOMYELITIS
    1) WITH POISONING/EXPOSURE
    a) Severe cases may progress to encephalitis, which has been characterized by seizures, meningeal signs or meningitis, tremor, delirium, stupor, coma, spastic paralysis, abnormal reflexes, cranial nerve palsies, nystagmus, nuchal rigidity and central respiratory failure. Most severe cases will result in residual neurologic damage (Douglas, 1996; Sanford, 1994). Children are more likely to develop VEE-associated encephalitis (Paessler & Weaver, 2009).
    b) CNS pathologic findings in severe encephalitis cases have included edema, meningeal and perivascular inflammation, intracerebral hemorrhages, neuronal degeneration, and vasculitis (Douglas, 1996).
    c) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, encephalitis (9%) occurred infrequently (Quiroz et al, 2009).
    F) CSF CELL CONTENT: RAISED
    1) WITH POISONING/EXPOSURE
    a) The cerebrospinal fluid contains up to 500 cells per cubic millimeter (predominantly lymphocytes) in the most severe cases of encephalitis (Douglas, 1996). Pleocytosis with modest increases in protein and normal glucose concentrations have been reported (Sanford, 1994).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) NAUSEA, VOMITING AND DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) Onset of nausea and vomiting generally occurs following an initial period of a flu-like illness. Occasionally diarrhea occurs during the same time frame (Douglas, 1996; Sanford, 1994).
    B) NAUSEA AND VOMITING
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, nausea (21%) and vomiting (21%) were common (Quiroz et al, 2009).
    C) DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, diarrhea (9%) occurred infrequently (Quiroz et al, 2009).

Hepatic

    3.9.2) CLINICAL EFFECTS
    A) LIVER ENZYMES ABNORMAL
    1) WITH POISONING/EXPOSURE
    a) In severe cases, hepatic enzymes (serum LDH and glutamic-oxaloacetic transaminase) may be elevated. Pathologic liver changes have included hepatocellular degeneration and necrosis (Douglas, 1996).
    B) HEPATIC FAILURE
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, hepatic failure (3%) occurred rarely (Quiroz et al, 2009).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, renal failure (3%) occurred rarely (Quiroz et al, 2009).

Hematologic

    3.13.1) SUMMARY
    A) Low peripheral leukocyte count has been reported in severe cases.
    3.13.2) CLINICAL EFFECTS
    A) LEUKOPENIA
    1) WITH POISONING/EXPOSURE
    a) Often the peripheral leukocyte count is decreased, with decreases in both lymphocytes and neutrophils. The peripheral leukocyte count is less often normal, with a relative lymphopenia (Douglas, 1996). In some cases a striking leukopenia and lymphopenia may be present. Leukopenia has been reported in two-thirds of patients by the third day of illness (Sanford, 1994). In one case, leukopenia was noted 2 weeks after the onset of illness (Mangiafico et al, 2002).
    B) HEMORRHAGE
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, hemorrhage (3%) occurred rarely (Quiroz et al, 2009).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) PURPURA
    1) WITH POISONING/EXPOSURE
    a) Petechiae over the distal forearms and hands was reported in the early stages of VEE in one case (Mangiafico et al, 2002).
    B) ERUPTION
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, rash (3%) occurred rarely (Quiroz et al, 2009).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) JOINT PAIN
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, renal failure (3%) occurred rarely (Quiroz et al, 2009).
    B) MUSCLE PAIN
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, myalgia (21%) occurred frequently (Quiroz et al, 2009).
    C) BACKACHE
    1) WITH POISONING/EXPOSURE
    a) CASE SERIES: In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by nausea, vomiting, diarrhea, fever, headache and tremors. Of the 33 cases that exhibited clinical adverse events, back pain (6%) occurred infrequently (Quiroz et al, 2009).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) LYMPHADENOPATHY
    1) WITH POISONING/EXPOSURE
    a) Lymphadenopathy is common, and may be seen in up to one-third of patients during the acute phase of illness (Sanford, 1994).

Reproductive

    3.20.1) SUMMARY
    A) Fetal encephalitis and hydranencephaly has been reported. VEE virus may be embryotoxic, fetotoxic, and teratogenic to humans.
    3.20.2) TERATOGENICITY
    A) MICROCEPHALY
    1) Fetal encephalitis, which may occur during the first and second trimesters, may progress to massive and widespread necrosis of brain tissue, hemorrhages, and resorption of brain material, resulting in hydranencephaly. In one infant the absence of a cerebellum was reported (Douglas, 1996; Sever, 1985). In 3 cases of human maternal exposure, postmortem examinations of the fetuses showed massive necrosis and hemorrhage of the cerebrum and cerebellum, with signs of brain resorption. A stillborn 33-week-old fetus was reported with microcephaly, microphthalmia, hypoplasia of the medulla, small remnant rests of neural tissue in the cranial cavity, and subluxed hips (Casamassima et al, 1987).
    2) CASE REPORT - Immunization with TC-83, a live attenuated Venezuelan equine encephalitis virus vaccine, during the first trimester of pregnancy resulted in hydrops fetalis and fetal demise. Postmortem examination showed marked autolysis of the brain. Hydrops was shown by generalized subcutaneous edema, hydrothorax, ascites, and a large multi-lobulated cystic hygroma (Casamassima et al, 1987).
    B) ABORTION
    1) Increased rates of abortions and stillbirths have been reported in studies of epidemics of Venezuelan equine encephalitis in Latin America. A high frequency of abortions was reported in women with encephalitis (Sever, 1985).
    C) CNS EFFECTS
    1) Children whose mothers had encephalitis between week 13 and 36 of pregnancy tended to have severe damage of the central nervous system (Sever, 1985a). Some of these children had microphthalmia, no cerebellum, and only small nests of nervous tissue in the cranial cavities. Massive brain necrosis was evident in some cases.
    D) ANIMAL STUDIES
    1) Studies of female monkeys given VEE virus vaccine has shown that fetal infections have resulted in brain damage and cataracts in the offspring (Sever, 1985).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Monitor vital signs, including temperature and pulse.
    B) No specific studies are needed in most patients that develop mild flu-like illness. Monitor fluid status and electrolytes in patients that develop significant vomiting and/or diarrhea.
    C) Monitor liver function tests and complete blood count as indicated.
    D) Monitor for respiratory depression and hypoxia (pulse oximetry or arterial blood gases) in any patient with encephalitis.
    E) Obtain cranial CT and lumbar puncture in patients with altered mental status.
    F) Diagnosis may be established by electron microscopic identification of virus particles isolated from blood or throat swabs obtained in the acute phase of illness. Serological antibody tests confirm the diagnosis and may be more practical. Detection of virus-specific IgM antibody in cerebrospinal fluid is diagnostic.
    4.1.2) SERUM/BLOOD
    A) TOXICITY
    1) Venezuelan encephalitis virus (VEE) can be isolated from blood or from throat swabs or washings within the first 3 to 4 days of illness and identified by electron microscopy (Douglas, 1996). Serodiagnosis is considered more practical.
    B) BLOOD/SERUM CHEMISTRY
    1) Monitor liver function tests, particularly enzyme levels, which may be elevated during the earlier phases of illness.
    C) HEMATOLOGIC
    1) Monitor complete blood cell counts. White blood cell count generally shows a striking leukopenia and lymphopenia in approximately two-thirds of patients by the third day of illness (Sanford, 1994) (USAMRIID, 1999).
    4.1.4) OTHER
    A) OTHER
    1) CEREBROSPINAL FLUID
    a) Cerebrospinal fluid in cases of encephalitis may contain up to 1000 white cells/mm(3) (predominantly mononuclear cells) and a mildly increased protein concentration (USAMRIID, 1999) (Douglas, 1996). Pleocytosis with modest increases in protein and normal glucose concentrations have been reported (Sanford, 1994).
    2) MONITORING
    a) Patients with signs/symptoms of encephalitis may progress to a central respiratory failure. Monitor respiratory function in patients with encephalitis.

Methods

    A) IMMUNOASSAY
    1) Serodiagnosis is the most practical method of diagnosis and is achieved by testing appropriately timed paired sera by hemagglutination inhibition, complement fixation, IgM ELISA indirect FA, neutralization, or IgM immunoassay (USAMRIID, 1999) (Douglas, 1996). Presumptive diagnosis, in a patient without prior exposure to VEE viruses, may be made by finding IgM antibody in a single serum sample taken 5 to 7 days following onset of illness (USAMRIID, 1999).
    2) In one case, USAMRIID isolated virus from acute phase serum and then tested infected cells against a panel of viral grouping fluids via an indirect fluorescent antibody (IFA) assay. The virus was identified as VEE, subtype ID virus by monoclonal antibodies; this was confirmed by cross plaque-reduction neutralization tests (Mangiafico et al, 2002).
    3) A dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) was developed for the detection of VEE virus. This was compared with ELISA to determine sensitivity or limit of detection (LOD), dynamic range, and reproducibility. An increased LOD, resulting in higher sensitivity, was reported for DELFIA; however, reproducibility of DELFIA was poor. DELFIA appeared to be a rapid and highly sensitive method of detection; however, the assays were cumbersome to perform and difficult to interpret (Smith et al, 2001).

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.6) DISPOSITION/BITE-STING EXPOSURE
    6.3.6.1) ADMISSION CRITERIA/BITE-STING
    A) Unstable patients or those with worsening symptoms should be admitted to the hospital. Those with severe symptoms (eg, seizures, encephalitis, coma) may require an ICU admission. Criteria for discharge include patients that are clinically improving and stable. INHALATION: All patients with suspected inhalational VEE infection should be admitted to an isolated intensive care unit for monitoring.
    6.3.6.2) HOME CRITERIA/BITE-STING
    A) Asymptomatic patients or patients with minimal symptoms may remain at home.
    6.3.6.3) CONSULT CRITERIA/BITE-STING
    A) Infectious disease physicians and/or intensivists may be consulted for advice on treating patients. All suspected cases should be reported to the state health department, which in turn notifies the CDC. Persons with conjunctiva exposure to blood, body fluids, secretions, or excretions from a patient with suspected VEE should receive medical evaluation and follow-up management. Health department personnel will work with the CDC and the attending physician(s) in the treatment of VEE. Poison centers can aid treatment by serving as a public health resource by providing advice to the general public, and working with local and regional health departments.
    6.3.6.4) PATIENT TRANSFER/BITE-STING
    A) If a patient must be transferred, strict isolation procedures should be observed by all personnel involved in the transfer.
    6.3.6.5) OBSERVATION CRITERIA/BITE-STING
    A) Patients with worsening symptoms that do not improve with over-the-counter medications (eg, analgesics, antipyretics) and basic home treatments should go to a healthcare facility for evaluation and treatment. Patients who are stable with improving symptoms may be sent home.

Monitoring

    A) Monitor vital signs, including temperature and pulse.
    B) No specific studies are needed in most patients that develop mild flu-like illness. Monitor fluid status and electrolytes in patients that develop significant vomiting and/or diarrhea.
    C) Monitor liver function tests and complete blood count as indicated.
    D) Monitor for respiratory depression and hypoxia (pulse oximetry or arterial blood gases) in any patient with encephalitis.
    E) Obtain cranial CT and lumbar puncture in patients with altered mental status.
    F) Diagnosis may be established by electron microscopic identification of virus particles isolated from blood or throat swabs obtained in the acute phase of illness. Serological antibody tests confirm the diagnosis and may be more practical. Detection of virus-specific IgM antibody in cerebrospinal fluid is diagnostic.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) DECONTAMINATION
    1) Oral exposure is unlikely and is not a known mode of disease transmission. The effectiveness of gastrointestinal decontamination measures following oral exposure to Venezuelan equine encephalitis (VEE) viruses is not known.
    2) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).
    3) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).

Inhalation Exposure

    6.7.2) TREATMENT
    A) SUPPORT
    1) Treatment should include recommendations listed in the BITES/STINGS EXPOSURE section when appropriate.
    B) BLOOD AND FLUIDS PRECAUTIONS
    1) Medical personnel working with known Venezuelan equine encephalitis (VEE) infected patients should wear protective masks and utilize barrier isolation techniques. Droplet precautions are indicated in all patients.
    2) Although the primary mechanism of infection is via bites from a carrier mosquito, a secondary, although rare, mechanism of infection may be through respiratory droplets.
    3) A monoclonal antibody has been developed, and is in the animal test phase, for protection against infection and disease when given before or up to 24 hours after an airborne challenge with virulent virus. Therapeutic activity was dependent on both prevention of virus infection of the brain and rapid clearance of virus from the periphery (Phillpotts et al, 2002). Live attenuated virus vaccine, TC-83, is available as an investigational drug for laboratory personnel working with the virus. Dose of the vaccine is 0.5 mL subcutaneously once. Protection appears to be short-lived, with significant breakthrough infection at 6 to 8 months post-vaccination (Elvin et al, 2002).

Eye Exposure

    6.8.1) DECONTAMINATION
    A) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) DERMAL DECONTAMINATION
    1) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.9.2) TREATMENT
    A) SUPPORT
    1) Treatment should include recommendations listed in the BITES/STINGS EXPOSURE section when appropriate.

Summary

    A) TOXICITY: The number of aerosolized viruses needed to cause viremia in humans is 10 to 100 organisms. Infections chiefly present with chills and fever, malaise, headache, and myalgia, usually self-limited, and resolve over one week. More severe cases progress to encephalitis with severe neurologic abnormalities, including seizures, nystagmus, somnolence, delirium, or meningitis.

Minimum Lethal Exposure

    A) CASE SERIES
    1) In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by fever, headache, nausea, vomiting, diarrhea, and tremors. Of the 39 cases with known outcomes, 2 deaths were reported for a case fatality rate of 5% (Quiroz et al, 2009).

Maximum Tolerated Exposure

    A) CASE SERIES
    1) In a study of 42 cases of endemic VEE detected in Panama from 1961 to 2004 most clinical signs and symptoms were characterized by fever, headache, nausea, vomiting, diarrhea, and tremors. Of 39 cases with known outcomes, 2 deaths were reported for a case fatality rate of 5% (Quiroz et al, 2009).
    B) ADULT
    1) Approximately 10 to 100 aerosolized organisms are required for infectivity in humans, with an incubation period of 2 to 6 days and a duration of illness of days to weeks. The persistence of the organism is rated as relatively unstable (USAMRIID, 1999).

Toxicologic Mechanism

    A) Venezuelan equine encephalitis (VEE) is caused by an RNA arbovirus of the alphavirus genus, which is a member of the Togaviridae family (Anon, 1997). The causative agent of VEE is a 40- to 45-nm, single-stranded RNA virus (Sanford, 1994). Serologic tests have identified 6 antigenic subtypes (I to VI) with multiple antigenic variants of subtypes I and III. Epidemics involving humans are caused by subtypes IAB and IC, and in Florida, subtype II is enzootic and has caused sporadic human disease (Douglas, 1996). VEE virus causes severe disease in horses, mules, burros and donkeys (Equidae). Equidae serve as amplifying hosts and a source of mosquito infection. Severe encephalitis in Equidae always precedes disease in humans in natural human epidemics.
    B) TRANSMISSION - Alphaviruses are transmitted by the bite of a mosquito. Equidae or other mammals serve as amplifying hosts and source of mosquito infection. During epizootic epidemics, a large variety of mosquito vectors transmit subtypes IAB and IC of the VEE. The principle viremic hosts are equines, but the virus may be present in human pharyngeal excretions. Contact or aerosol person-to-person spread is possible, but has not been epidemiologically significant in the past (Douglas, 1996). As a method of biologic or terrorism attacks, this could become significant. Laboratory infections have occurred, probably due to inhalation of aerosols (Sanford, 1994).
    1) Human disease has occurred, although sporadic and fairly uncommon, due to subtype II enzootic transmission cycles in Florida. These outbreaks have involved Culex (Melanoconion) species mosquitoes and small forest rodent and marsupials as vectors (Douglas, 1996).
    C) During the flu-like illness stage, some patients with viremia may exhibit evidence of CNS involvement, which may progress to severe encephalitis. Cases presenting with encephalitis may have a mortality rate approaching 50% (Rosen, 1998). In severe cases, residual neurologic damage may also occur.
    D) VEE virus replicates in lymphoid tissues following peripheral inoculation. Dissemination through the lymphatic system has been shown in mice, with moderate infiltration of acute inflammatory cells into draining and systemic lymph nodes, occurring by 24 hours post infection. Pathological changes occur in the spleen during this time and the virus replicates in non-lymphoid organs (i.e., pancreas, heart, and gut) (Elvin et al, 2002).
    1) Normal cells begin to re-populate lymphoid tissues by 5 days post-infection, with virus clearance from visceral organs on days 5 and 6 post-infection. In the second phase of infection occurring 2 or 3 days post-infection, the virus invades the CNS, replicating in neurons and persisting in the brain until recovery or death by encephalitis which occurs on day 6 to 7 post-infection.
    E) Following an aerosol challenge in mice, the virus was shown to replicate within the nasal mucosa and within the olfactory sensory neurons located there. By spreading along the axons of the chemosensory olfactory neurons, the virus was able to access the brain (Elvin et al, 2002).

General Bibliography

    1) AMA Department of DrugsAMA Department of Drugs: AMA Evaluations Subscription, American Medical Association, Chicago, IL, 1992.
    2) Anon: Arboviruses. AAP 1997 Red Book: Report of the Committee on Infectious Disease, 24th ed, American Academy of Pediatrics, Montvale, NJ, 1997.
    3) Anon: Venezuelan equine encephalitis. Office of the Surgeon General Medical NBC. Washington, DC, USA. 1999. Available from URL: http://www.nbc-med.org/sitecontent/medref/onlineref/fieldmanuals/medman/Venezuelan.htm. As accessed Accessed July 28, 1999.
    4) Brophy GM, Bell R, Claassen J, et al: Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17(1):3-23.
    5) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    6) Casamassima AC, Hess LW, & Marty A: TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy. Teratology 1987; 36:287-289.
    7) Chamberlain JM, Altieri MA, & Futterman C: A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care 1997; 13:92-94.
    8) Chin RF , Neville BG , Peckham C , et al: Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7(8):696-703.
    9) Choonara IA & Rane A: Therapeutic drug monitoring of anticonvulsants state of the art. Clin Pharmacokinet 1990; 18:318-328.
    10) Douglas RG: Venezuelan equine encephalitis (VEE), in Bennett: Cecil Textbook of Medicine, 20th ed , WB Saunders Company, Philadelphia, PA, 1996.
    11) Elvin SJ, Bennett AM, & Phillpotts RJ: Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J Med Virol 2002; 67:384-393.
    12) Franz DR, Jahrling PB, & Friedlander AM: Clinical recognition and management of patients exposed to biological warfare agents. J Am Med Assc 1997; 278:399-411.
    13) Hegenbarth MA & American Academy of Pediatrics Committee on Drugs: Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121(2):433-443.
    14) Hvidberg EF & Dam M: Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976; 1:161.
    15) Loddenkemper T & Goodkin HP: Treatment of Pediatric Status Epilepticus. Curr Treat Options Neurol 2011; Epub:Epub.
    16) Mangiafico JA, Rossi CA, & Ludwig GV: Short report: isolation and identification of Venezuelan equine encephalitis virus from a human in Panama. Am J Trop Med Hyg 2002; 67:112-113.
    17) Manno EM: New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78(4):508-518.
    18) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    19) Paessler S & Weaver SC : Vaccines for Venezuelan equine encephalitis. Vaccine 2009; 27 Suppl 4:D80-D85.
    20) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    21) Phillpotts RJ, Jones LD, & Howard SC: Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002; 20:1497-1504.
    22) Product Information: CEREBYX(R) intravenous injection, fosphenytoin sodium intravenous injection. Pfizer Labs (per FDA), New York, NY, 2014.
    23) Product Information: Dilantin(R) intravenous injection, intramuscular injection, phenytoin sodium intravenous injection, intramuscular injection. Parke-Davis (per FDA), New York, NY, 2013.
    24) Product Information: diazepam IM, IV injection, diazepam IM, IV injection. Hospira, Inc (per Manufacturer), Lake Forest, IL, 2008.
    25) Product Information: lorazepam IM, IV injection, lorazepam IM, IV injection. Akorn, Inc, Lake Forest, IL, 2008.
    26) Quiroz E, Aguilar PV, Cisneros J, et al: Venezuelan equine encephalitis in Panama: fatal endemic disease and genetic diversity of etiologic viral strains. PLoS Negl Trop Dis 2009; 3(6):e472.
    27) Rosen P (Ed): Emergency Medicine: Concepts and Clinical Practice, 4th ed. Mosby-Year Book, Inc, St Louis, MO, 1998.
    28) Sanford JP: Arbovirus infections, in Isselbacher KJ, Braunwald E, Wilson JD et al (eds): Harrison's Principles of Internal Medicine, 13 th ed, McGraw-Hill, Inc, New York, NY, 1994, pp 837-839.
    29) Scott R, Besag FMC, & Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
    30) Sever JL: Approaches used for the detection of infectious agents as human teratogens. Prog Clin Biol Res 1985a; 163C:215-220.
    31) Sever JL: Changing perspectives of the effects of infectious diseases. Prog Clin Biol Res 1985; 163:135-142.
    32) Smith DR, Rossi CA, & Kijek TM: Comparison of dissociation-enhanced lanthanide fluorescent immunoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, Yersinia pestis-specific F1 antigen, and Venezuelan equine encephalitis virus. Clin Diag Lab Immunol 2001; 8:1070-1075.
    33) Sreenath TG, Gupta P, Sharma KK, et al: Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol 2009; Epub:Epub.
    34) Tretyakova I , Lukashevich IS , Glass P , et al: Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine 2013; 31(7):1019-1025.
    35) Wallace KL: Toxin-Induced Seizures. In: Brent J, Wallace KL, Burkhart KK, et al, eds. Critical Care Toxicology, Elsevier Mosby, Philadelphia, PA, 2005.